Les carcinomes apocrines moléculaires du sein sont des tumeurs agressives n’exprimant pas RE mais surexprimant HER2 ou GCDFP15 von Amira-Bouhidel, F., Lehmann-Che, J., Hamy, A.-S., Porcher, R., Barritault, M., Habuellelah, H., Lemann-Detours, S., de Roquancourt, A., Cahen-Doidy, L., Bourstyn, E., de Cremoux, P., de Bazelaire, C., Albiter, M., Giacchetti, S., Cuvier, C., Janin, A., Espié, M., de Thé, H., Bertheau, P.

Volltext

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 von Lehmann-Che, Jacqueline, Hamy, Anne-Sophie, Porcher, Raphaël, Barritault, Marc, Bouhidel, Fatiha, Habuellelah, Hanadi, Leman-Detours, Solenne, de Roquancourt, Anne, Cahen-Doidy, Laurence, Bourstyn, Edwige, de Cremoux, Patricia, de Bazelaire, Cedric, Albiter, Marcela, Giacchetti, Sylvie, Cuvier, Caroline, Janin, Anne, Espié, Marc, de Thé, Hugues, Bertheau, Philippe

Volltext

St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up von Falck, A. K., Röme, A., Fernö, M., Olsson, H., Chebil, G., Bendahl, P. O., Rydén, L.

Volltext

ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See von Chamandi, Ghada, El-Hajjar, Layal, El Kurdi, Abdallah, Le Bras, Morgane, Nasr, Rihab, Lehmann-Che, Jacqueline

Volltext

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers von Jacot, William, Maran-Gonzalez, Aurélie, Massol, Océane, Sorbs, Charlotte, Mollevi, Caroline, Guiu, Séverine, Boissière-Michot, Florence, Ramos, Jeanne

Volltext

Low-risk triple-negative breast cancers: Clinico-pathological and molecular features von Fusco, Nicola, Sajjadi, Elham, Venetis, Konstantinos, Ivanova, Mariia, Andaloro, Silvia, Guerini-Rocco, Elena, Montagna, Emilia, Caldarella, Pietro, Veronesi, Paolo, Colleoni, Marco, Viale, Giuseppe

Volltext

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors von Daemen, Anneleen, Manning, Gerard

Volltext

Triple negative breast cancer: special histological types and emerging therapeutic methods von Cao, Lu, Niu, Yun

Volltext

FOXA1 is a determinant of drug resistance in breast cancer cells von Kumar, Uttom, Ardasheva, Anastasia, Mahmud, Zimam, Coombes, R. Charles, Yagüe, Ernesto

Volltext

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts von Coussy, Florence, Lavigne, Marion, de Koning, Leanne, Botty, Rania El, Nemati, Fariba, Naguez, Adnan, Bataillon, Guillaume, Ouine, Berengère, Dahmani, Ahmed, Montaudon, Elodie, Painsec, Pierre, Chateau-Joubert, Sophie, Laetitia, Fuhrmann, Larcher, Thibaut, Vacher, Sophie, Chemlali, Walid, Briaux, Adrien, Melaabi, Samia, Salomon, Anne Vincent, Guinebretiere, Jean Marc, Bieche, Ivan, Marangoni, Elisabetta

Volltext

Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies von Pescia, Carlo, Guerini-Rocco, Elena, Viale, Giuseppe, Fusco, Nicola

Volltext

CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3 von Porras, Lucas, Gorse, Faustine, Thiombane, Ndeye Khady, Gaboury, Louis, Mader, Sylvie

Volltext

A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated wi... von Hamy, Anne-Sophie, Bonsang-Kitzis, Hélène, Lae, Marick, Moarii, Matahi, Sadacca, Benjamin, Pinheiro, Alice, Galliot, Marion, Abecassis, Judith, Laurent, Cecile, Reyal, Fabien

Volltext

Apocrine lesions of breast and invasive carcinoma with apocrine differentiation: a brief review von Anjum, Saba, Mooghal, Mehwish, Rehman, Abdul, Sellal, Yusra, Vohra, Lubna

Volltext

Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? von Anestis, Aristomenis, Karamouzis, Michalis V, Dalagiorgou, Georgia, Papavassiliou, Athanasios G

Volltext

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts von de Cremoux, Patricia, Dalvai, Mathieu, N’Doye, Olivia, Moutahir, Fatima, Rolland, Gaëlle, Chouchane-Mlik, Olfa, Assayag, Franck, Lehmann-Che, Jacqueline, Kraus-Berthie, Laurence, Nicolas, André, Lockhart, Brian Paul, Marangoni, Elisabetta, de Thé, Hugues, Depil, Stéphane, Bystricky, Kerstin, Decaudin, Didier

Volltext

Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer von Sauer, Natalia, Matkowski, Igor, Bodalska, Grażyna, Murawski, Marek, Dzięgiel, Piotr, Calik, Jacek

Volltext

Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers von Vranic, Semir, Feldman, Rebecca, Gatalica, Zoran

Volltext

Androgen receptor- and PIAS1-regulated gene programs in molecular apocrine breast cancer cells von Malinen, Marjo, Toropainen, Sari, Jääskeläinen, Tiina, Sahu, Biswajyoti, Jänne, Olli A., Palvimo, Jorma J.

Volltext

Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity von Sriram, Roshan, Lo, Vivian, Pryce, Benjamin, Antonova, Lilia, Mears, Alan J, Daneshmand, Manijeh, McKay, Bruce, Conway, Simon J, Muller, William J, Sabourin, Luc A

Volltext